查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601230

胚胎着床前基因检测市场：按技术、产品、程序类型、应用、最终用户 - 2025-2030 年全球预测

Preimplantation Genetic Testing Market by Technology, Offering, Procedure Type, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，胚胎着床前基因检测市值为7.284亿美元，预计2024年将达到8.2906亿美元，复合年增长率为14.56%，到2030年将达到18亿美元，预计将达到8628万美元。

胚胎着床前基因检测（PGT）是一种用于辅助生殖技术的尖端测试，用于在胚胎着床前筛检胚胎是否有遗传疾病，目的是降低遗传疾病的风险。对PGT的需求源于对预防遗传疾病和健康妊娠结局日益增长的需求，特别是对于那些有遗传病史的人。 PGT 的主要用途是提供体外受精 (IVF) 服务的不孕症诊所和医院。最终用途范围从有遗传基因突变风险的夫妇到经历反覆流产或接受体外受精的夫妇。该市场的主要成长要素包括不孕率上升、遗传技术的进步、对遗传疾病的认识不断提高以及对基于遗传资讯的生殖选择的接受程度不断提高。持续的研发投资正在推动创新和市场扩张，其中个人化医疗和精准医疗处于领先地位。公司围绕着非侵入性筛检技术和增强的基因分析工具存在创新机会，由于风险更低和准确性更高，这可能会导致更广泛的采用。但有伦理考量、高成本、监管严格、发展中地区认知度低等限制。为了克服这些因素，需要广泛的教育措施和策略伙伴关係关係来推动普及和负担能力。市场相关人员可以专注于旨在降低成本的强有力的研发活动，同时提高 PGT 的有效性和安全性。此外，探索人工智慧在资料分析中的整合可以简化流程并提高预测准确性。强调与学术机构的合作可以刺激重要的创新。企业也应倡导政策，提高其服务的可近性，同时解决道德问题，以扩大其消费者基础。透过专注于这些途径，公司可以在不断发展的 PGT 领域获得竞争优势。

主要市场统计
基准年[2023] 7.284 亿美元
预测年份 [2024] 82906万美元
预测年份 [2030] 18.8628亿美元
复合年增长率（%） 14.56%

市场动态：快速发展的胚胎着床前基因检测市场的关键市场洞察

供需的动态交互作用正在改变着胚胎着床前基因检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 胎儿畸形发生率很高，需要健康、成功的胚胎移植
    • 全球不孕症患者数量增加，生育诊所数量增加
    • 早期诊断方法的增加以及政府对遗传疾病治疗的支持的增加
  • 市场限制因素
    • 与 PGT 相关的限制和风险
  • 市场机会
    • 胚胎着床前遗传分析领域的技术进展
    • 投资新兴企业生态系和胚胎着床前基因测试空间
  • 市场挑战
    • PGT 的道德约束和滥用

波特五力：驾驭胚胎着床前基因检测市场的策略工具

波特的五力框架是了解胚胎着床前基因检测市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胚胎着床前基因检测市场的外部影响

外部宏观环境因素在塑造胚胎着床前基因检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胚胎着床前基因检测市场的竞争格局

胚胎着床前基因检测市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵胚胎着床前基因检测市场供应商的绩效评估

FPNV定位矩阵是评估胚胎着床前基因检测市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胎儿畸形发生率高，需要健康、正常的胚胎移植
      • 全球不孕率上升和生育诊所数量增加
      • 扩大早期诊断方法并增加政府对遗传疾病治疗的支持
    • 抑制因素
      • 与 PGT 相关的限制和风险
    • 机会
      • 胚胎着床前遗传分析领域的技术进展
      • 胚胎胚胎着床前基因检测领域的新兴Start-Ups生态系与投资
    • 任务
      • PGT 的道德约束和滥用
  • 市场区隔分析
    • 技术：检测染色体异常和单基因疾病的次世代定序技术取得进展
    • 我们提供什么：利用各种服务来优化製程条件并获得准确的结果。
    • 步骤：更多采用胚胎着床前遗传学诊断 (PGD) 程序，以降低遗传疾病的风险
    • 应用：胚胎着床前基因检测广泛用于非整倍体疾病
    • 最终用户：医疗保健研究组织越来越多地采用 PGT，以实现准确诊断和有效治疗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章胚胎着床前基因检测市场：依技术分类

  • 比较杂合反应
  • 萤光原位杂合技术
  • 次世代定序
  • 聚合酵素链锁反应
  • 单核苷酸多态性

第七章胚胎着床前基因检测市场：透过提供

  • 装置
  • 试剂/耗材
  • 软体和服务

第八章按程序类型胚胎着床前基因检测市场

  • 胚胎着床前遗传学诊断
  • 胚胎着床前基因筛检

第九章胚胎着床前基因检测市场：依应用分类

  • 非整倍体
  • 性别认同
  • HLA型检测
  • 单基因疾病
  • 染色体结构异常
    • 删除
    • 复製
    • 反转
    • 易位
  • X连锁疾病

第 10 章胚胎着床前基因检测市场：依最终用户分类

  • 委託调查/製造组织
  • 冷冻库
  • 医院、诊断实验室、服务供应商
  • 研究实验室和学术机构

第十一章美洲胚胎着床前基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太胚胎着床前基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲胚胎着床前基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Natera 从 Invitae 收购产前筛检和携带者筛检资产，以加强病患服务和市场地位
    • Thermo Fisher Scientific 推出用于胚胎着床前基因检测的先进定序工具，以改善不孕症研究和生殖医学的结果。
    • Medicover Genetics 和 FimLab Laboratories 宣布合作在芬兰提供基因检测服务
    • 美国 Fertility 和 Ovation 合併成为领先的 IVF 服务公司，改善生育治疗服务的可近性
    • Eurofins Genoma 宣布推出 niPGT-A，一种非侵入性、免切片检查的胚胎着床前遗传非整倍体筛检测试
    • GenEmbryomics 推出有史以来最全面的 IVF 基因检测
    • 接受体外受精的新加坡人获得某些类型治疗的新资金
    • 澳洲 Fertilis 融资 200 万美元用于自动化 IVF 胚胎培养

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Bioarray SL
  • EUROPE IVF International sro
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market was valued at USD 728.40 million in 2023, expected to reach USD 829.06 million in 2024, and is projected to grow at a CAGR of 14.56%, to USD 1,886.28 million by 2030.

Preimplantation Genetic Testing (PGT) is a cutting-edge procedure used to examine embryos for genetic diseases before implantation during assisted reproduction, aiming to reduce the risk of inherited conditions. Its necessity arises from the increasing demand for genetic disease prevention and healthy pregnancy outcomes, especially for individuals with a history of genetic disorders. The application of PGT predominantly lies in fertility clinics and hospitals that offer in vitro fertilization (IVF) services. The end-use scope ranges from couples at risk of passing on genetic mutations to those experiencing recurrent pregnancy losses or undergoing IVF. Key growth factors in this market include rising infertility rates, advances in genetic technologies, growing awareness about genetic disorders, and increasing acceptance of genetically informed reproductive choices. There is a continuous pour of investment in research and development, driving innovation and market expansion, with personalized medicine and precision healthcare gaining traction. Opportunities exist for businesses to innovate around non-invasive screening techniques and enhanced genetic analysis tools, representing the potential to widen adoption due to lower risks and increased accuracy. However, limitations include ethical considerations, high costs, strict regulations, and limited awareness in developing regions. Overcoming these factors requires extensive educational initiatives and strategic partnerships to drive adoption and affordability. Market players can focus on robust R&D efforts aimed at reducing costs while enhancing the efficacy and safety of PGT. Additionally, exploring the integration of artificial intelligence in data analysis could streamline processes and improve predictive accuracy. Emphasizing collaborations with academic institutions might spur key innovations. Businesses should also advocate for policies enhancing service accessibility while addressing ethical concerns to broaden their consumer base. By concentrating on these paths, firms can gain a competitive edge in the evolving landscape of PGT.

KEY MARKET STATISTICS
Base Year [2023] USD 728.40 million
Estimated Year [2024] USD 829.06 million
Forecast Year [2030] USD 1,886.28 million
CAGR (%) 14.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preimplantation Genetic Testing Market

The Preimplantation Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
    • Increase in the rate of infertility and the rising number of fertility clinics worldwide
    • Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
  • Market Restraints
    • Limitation and risks associated with PGT
  • Market Opportunities
    • Technological advancement in the field of preimplantation genetic analysis
    • Emerging startup ecosystem and investments in the field of preimplantation genetic testing
  • Market Challenges
    • Ethical constraints and Misuse of PGT

Porter's Five Forces: A Strategic Tool for Navigating the Preimplantation Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preimplantation Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preimplantation Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preimplantation Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preimplantation Genetic Testing Market

A detailed market share analysis in the Preimplantation Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preimplantation Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preimplantation Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Comparative Genomic Hybridization, Fluorescence in-Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction, and Single-Nucleotide Polymorphism.
  • Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Procedure Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.
  • Based on Application, market is studied across Aneuploidy, Gender Identification, HLA Typing, Single Gene Disorders, Structural Chromosomal Abnormalities, and X-Linked Disorders. The Structural Chromosomal Abnormalities is further studied across Deletions, Duplications, Inversions, and Translocations.
  • Based on End User, market is studied across Contract Research & Manufacturing Organizations, Cryobanks, Hospitals, Diagnostic Labs, & Service Providers, and Research Laboratories & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
      • 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
      • 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Limitation and risks associated with PGT
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
      • 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical constraints and Misuse of PGT
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
    • 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
    • 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
    • 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
    • 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Comparative Genomic Hybridization
  • 6.3. Fluorescence in-Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction
  • 6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
  • 7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Preimplantation Genetic Diagnosis
  • 8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Aneuploidy
  • 9.3. Gender Identification
  • 9.4. HLA Typing
  • 9.5. Single Gene Disorders
  • 9.6. Structural Chromosomal Abnormalities
    • 9.6.1. Deletions
    • 9.6.2. Duplications
    • 9.6.3. Inversions
    • 9.6.4. Translocations
  • 9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research & Manufacturing Organizations
  • 10.3. Cryobanks
  • 10.4. Hospitals, Diagnostic Labs, & Service Providers
  • 10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
    • 14.3.2. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
    • 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
    • 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
    • 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
    • 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
    • 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
    • 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Bio-Techne Corporation
  • 5. Bioarray S.L.
  • 6. EUROPE IVF International s.r.o.
  • 7. F. Hoffmann-La Roche AG
  • 8. Genea Limited
  • 9. GENETiKS
  • 10. Illumina, Inc.
  • 11. Invicta Genetics
  • 12. Invitae Corporation
  • 13. Juno Genetics, US Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. MedGenome Labs Ltd.
  • 16. Merck KGaA
  • 17. Natera, Inc.
  • 18. NextGen Genetics Holdings, LLC
  • 19. Ovation Fertility
  • 20. PacGenomics
  • 21. PerkinElmer, Inc.
  • 22. Progyny, Inc.
  • 23. Qiagen N.V.
  • 24. Quest Diagnostics Incorporated
  • 25. Reproductive Genetic Innovations, LLC
  • 26. SEQUENCE46, LLC
  • 27. Sysmex Corporation
  • 28. Takara Bio Inc.
  • 29. The Cooper Companies Inc.
  • 30. Thermo Fisher Scientific Inc.
  • 31. Vitrolife Sweden AB
  • 32. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023